Renal Cell Cancer Metastatic Clinical Trial
Official title:
Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer
Verified date | February 2018 |
Source | Western Regional Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.
Status | Terminated |
Enrollment | 7 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients must have a histologic diagnosis of metastatic kidney cancer. Patients may have received prior systemic therapy or may be previously untreated 2. Patients must have bi-dimensional measurable disease on physical exam or radiologic studies. 3. ECOG performance status of 0 or 1 and estimated survival of at least 3 months. 4. White blood count of > 3500/mm3, platelet count > 100,000/mm3, hemoglobin > 9.0 gm/dl; bilirubin, ALT, AST < 3 x upper limit of normal; serum creatinine < 2.0 mg/dl. 5. Patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial. 6. Patients with elevated temperatures > 100.5 F must have sources of occult infection excluded. 7. Patients must be felt to have recovered from effects of prior therapy, such as > 2 weeks after prior chemotherapy. 8. Patient consent must be obtained prior to entrance onto study. 9. Women of childbearing potential must have a negative pregnancy test and must take adequate precautions to prevent pregnancy during treatment Exclusion Criteria: 1. Medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate. 2. Autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy. 3. Prior history of psychiatric disorder which could be exacerbated by interleukin-2. 4. Lactation or pregnancy. 5. Evidence of significant cardiovascular disease including history of recent (< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional PVC's, angina, positive low-level stress test, or cerebrovascular accident. 6. Current brain metastasis. |
Country | Name | City | State |
---|---|---|---|
United States | Western Regional Medical Center, Inc | Goodyear | Arizona |
Lead Sponsor | Collaborator |
---|---|
Western Regional Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Response Using RECIST Criteria | Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. Standard RECIST response criteria were utilized. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = 100%(CR + PR/total number of patients receiving Interleukin-2). | Measured until Disease Progression or death from any cause up to 2 year | |
Secondary | Median Duration of Response | Duration of response is calculated as the time (months) from the date at which response is first observed (per standard Response Evaluation Criteria In Solid Tumors [RECIST] to the date of first observed disease progression or date of death from any cause, whichever came first, assessed up to 2 years. The actual date of tumor assessments was used for this calculation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of one or more new lesions. | Measured from first response until Disease Progression or death from any cause up to 2 years | |
Secondary | Median Survival | from time of study entry until death | measured from date of first dose until date of death |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Completed |
NCT04368546 -
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
|
||
Recruiting |
NCT04903873 -
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06264479 -
Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2
|
||
Terminated |
NCT03876925 -
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
|
Phase 1/Phase 2 | |
Completed |
NCT01658813 -
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05326620 -
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
|
||
Active, not recruiting |
NCT03095040 -
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
|
Phase 3 | |
Completed |
NCT04749602 -
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
|
Phase 2 |